tions. Relative effectiveness for glycaemic control (HbA 1c ) and hypoglycaemia was determined from pivotal clinical trials. RESULTS: Pooled analysis of pre-registration studies showed no difference in HbA 1c between glargine-treated patients and NPH but did show a 28% risk reduction in severe hypoglycaemic episodes and a 22% risk reduction in nocturnal hypoglycaemic episodes compared to NPH. Over 40 years, treatment with NPH resulted in 42,518 additional severe hypoglycaemic events and 662,698 additional nocturnal hypoglycaemic events compared to insulin glargine. The discounted incremental cost effectiveness ratio (ICER) was £12,302 per quality adjusted life year (QALY) gained. Sensitivity analyses showed these findings were robust. CONCLUSIONS: For any given degree of glycaemia, there was reduced likelihood of severe and nocturnal hypoglycaemia with glargine. Insulin glargine is cost-effective when used as basal insulin for the treatment of people with Type 1 Diabetes. The ICER is well within accepted thresholds for cost-effective treatments in the UK. The 2-year RESULT study demonstrated that rosiglitazone (RSG) + sulphonylurea (SU) induced a sustained increase in beta-cell function (BCF) (56%, p < 0.0001) compared to no change with SU alone (6% p = 0.41). This study explores the impact of modelling improved BCF on predicted lifetime health outcomes and health care expenditure in Spain. METHODS: DiDACT, a peer-reviewed published long-term model of T2DM, was used to project the natural lifetime progression of T2DM for 1000 Spanish patients with characteristics matched to those in the RESULT study (73% male, mean age 68.2 years, mean BMI 30 kg/m2). Following failure to maintain glycaemic target (HbA1C ≥ 7.5%) with intermediate dose of SU, up-titration of SU therapy was compared to RSG + SU combination. Future costs and outcomes were discounted at 5% per year. The original calibration of RSG in DiDACT was based primarily on insulin sensitization. Improved BCF can be represented by using an additive, multiplicative or combined approach. The additive representation assumes a one-off change independent of existing BCF. The multiplicative representation assumes the impact is proportionate to current BCF. RESULTS: The findings demonstrate that both multiplicative and additive approaches to representing RSG's effect on BCF result in reduced lifetime costs and increased Quality Adjusted Life-Years (QALYs) compared with the previous calibration, with costeffectiveness ratios falling well below both established thresholds and previous estimates. CONCLUSIONS: Each modelling method of the impact of improved BCF in the management of T2DM indicated that RSG is more cost-effective than previously estimated. The impact of RSG on BCF may be confirmed in next forthcoming long-term studies.
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PDB8 THE IMPACT OF IMPROVED BETA-CELL FUNCTION ON MODELLING THE COST-EFFECTIVENESS OF ROSIGLITAZONE IN THE MANAGEMENT OF TYPE 2 DIABETES IN SPAIN

PDB9 THE ECONOMIC BENEFIT OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN TYPE 2 NON INSULIN TREATED DIABETES PATIENTS IN SWITZERLAND
Holm MV, Schwenkglenks M, Szucs TD University of Basel, Basel, Switzerland OBJECTIVES: To examine if close control of blood glucose levels in patients with type 2 diabetes treated with diet restrictions or oral medication has an economic benefit. METHODS: A decision analytic model with a time horizon of eight years has been developed. Costs are assessed from the perspective of the Swiss health care system. Data on the efficacy of SMBG come from the large observational ROSSO study conducted in Germany. The economic endpoint is the impact of blood glucose monitoring on direct medical costs, taking into account reduced costs due to five major diabetes-related complications (myocardial infarction (MI), stroke, haemodialysis due to renal failure, blindness, and foot amputation), and assuming no difference in all other direct medical costs of diabetes. The clinical endpoint is quality adjusted life years (QALYs) gained. RESULTS: Selfmonitoring of blood glucose induces a cost saving of CHF1062 over eight years due to a reduction in the number of diabetesrelated complications. This hints at an annual budget saving in diabetes related complications of CHF21 Mio. per year, based on an estimate of 160000 non-insulin treated type 2 diabetes patients in Switzerland. In addition, the quality of life is improved for patients performing SMBG. A critical parameter is the number of test strips used. A sensitivity analysis shows that with a weekly consumption of more than 5.25 strips per patient, SMBG is no longer a dominant strategy. No related, evidencebased guidelines are currently available. CONCLUSIONS: The potential economic benefit of self-monitoring of blood glucose among non insulin dependent type 2 diabetes patients seems to be substantial in Switzerland, due to a reduction in long-term diabetes complications. METHODS: A validated diabetes model was used to project long-term cumulative incidence of complications, life expectancy (LE), quality-adjusted life expectancy (QALE) and lifetime costs for IAsp versus HSI. Markov modeling techniques were used to describe incidence and progression of complications (eye, renal and cardiovascular disease, and peripheral neuropathy), and Monte Carlo simulation accounted for uncertainty. Probabilities of complications and HbA1c-dependent adjustments were derived from landmark clinical and epidemiological studies. Cohort definition and intervention effects were taken from a 30-month multicenter, multinational, open-labeled phase III extension trial in patients with type 1 diabetes. Costs were retrieved from published sources and expressed in 2005 Swedish Kronor (SEK) from a societal perspective (human capital approach). LE, QALE and total costs were projected over a 50-year time horizon and discounted at 3% per annum. RESULTS: IAsp was associated with an increase in LE of 0.13 years (16.38 ± 0.17 versus 16.26 ± 0.17) and in QALE of 0.14 quality-adjusted life years (QALYs) (10.86 ± 0.11 versus 10.72 ± 0.11) compared to HSI. The cumulative incidence of most diabetes-related complications was estimated to be lower for IAsp versus HSI. Long-term direct costs were slightly higher with IAsp than with HSI (SEK 568,532 ± 13,682 versus 567,920 ± 15,127), leading to an incremental cost-effectiveness ratio of SEK 4373 per QALY gained for IAsp versus HSI. From a societal perspective, IAsp was life and cost saving (dominant) compared to HSI, assuming that workplace productivity improved with diabetes-related complications avoided. CONCLUSIONS: Over patient lifetimes, IAsp was projected to improve LE and QALE and reduce the cumulative incidence of diabetes-related complications, with cost savings from a societal perspective in Sweden, compared to HSI. To estimate the long-term clinical and economic outcomes associated with repaglinide or nateglinide therapy, both in combination with metformin, in patients with type 2 diabetes inadequately controlled with sulfonylurea or metformin monotherapy, or with low dose glybenclamide plus metformin in the Swedish setting. Based on the results of a recent 16-week clinical trial. METHODS: A published and validated, interactive computer model was adapted to project life expectancy (LE), quality-adjusted life expectancy (QALE), cumulative incidence of complications and costs in the Swedish setting. The model comprises a series of Markov sub-models that simulate the long-term incidence and progression of diabetes-related complications based on published data. Baseline cohort characteristics (mean age 55.8 years, duration of diabetes 7 years, HbA1c 8.4%, BMI 33 kg.m-2) and intervention effects were derived from the clinical trial. Costs were accounted from a societal perspective (treatment, complication and lost-productivity costs) and expressed in year 2005 Swedish Kronor (SEK) values. Clinical and cost outcomes were projected over a lifetime horizon and discounted at 3% per annum. RESULTS: Repaglinide + metformin was associated with an increase in LE of 0.21 years (9.82 ± 0.18 versus 9.61 ± 0.17) and in QALE of 0.17 quality-adjusted life years (6.34 ± 0.12 versus 6.17 ± 0.11) compared to nateglinide + metformin. There was a reduced cumulative incidence of diabetesrelated complications associated with repaglinide + metformin treatment, most notably for retinopathy and nephropathy, compared to nateglinide + meformin. Lifetime costs were lower for repaglinide + metformin compared to nateglinide + metformin from both a third party payer (SEK 337,897 ± 11,471 versus SEK 380,867 ± 13,226) and societal perspective (SEK 629, 525 ± 22, 446 versus SEK 647, 635 ± 21, 191) . CONCLUSIONS: Treatment with repaglinide + metformin was projected to be associated with increased time free of diabetes-related complications and dominant (cost and life saving) from a societal perspective, compared to nateglinide + metformin, in the Swedish setting. Clinical and cost outcomes were projected over a lifetime horizon and discounted at a rate of 3% per annum. RESULTS: CSII treatment was associated with increased LE versus MDI in the Norwegian and Swedish settings (0.95 and 1.03 years, respectively) and increased QALE (0.98 and 1.03 quality-adjusted life years (QALYs), respectively). The cumulative incidence of diabetesrelated complications, particularly nephropathy and retinopathy complications was also lower in the CSII treatment arm compared to MDI. Mean lifetime costs were greater for CSII treatment compared to MDI in the Norwegian setting (NOK 3, 505, 368 ± 77, 645 versus 3, 480, 974 ± 76, 698) , which produced an incremental cost-effectiveness ratio (ICER) of NOK 24,837 (∼€3200) per QALY gained for CSII versus MDI. In the Swedish setting CSII was also associated with higher lifetime costs compared to MDI (SEK 3,026,056 ± 58,873 vs 2,965,366 ± 60,025) which led to an ICER of SEK 58,830 (∼€6300) per QALY gained for CSII versus MDI. CONCLUSIONS: CSII was associated with increased LE and QALE and reduced incidence of diabetes-related complications compared to MDI. CSII represents good value for money in the Norwegian and Swedish setting from a societal perspective by generally accepted standards. Cardiff University, Cardiff, South Glamorgan, UK, 2 Cardiff Research Consortium, Cardiff, South Glamorgan, UK, 3 sanofi-aventis UK, Guildford, Surrey, UK OBJECTIVES: The purpose of this study was to evaluate the relative cost effectiveness (cost utility) of insulin glargine versus NPH insulin in the UK for the treatment of people with type 2 diabetes mellitus (T2DM) using pooled data from the Phase III clinical trials programme. METHODS: This was a health economic evaluation using a stochastic simulation model. Transition probabilities for progression to diabetes-related complications for the model were derived mainly from the UKPDS (UK Prospective Diabetes Study) risk equations. Costs were derived from published estimates and local data. The maximum time horizon was 40 years to ensure effective modelling of diabetes
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